Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage: Analysis of Ischemic Myocardium at Risk Using Cardiac Magnetic Resonance

Background— &bgr;-Blockers improve clinical outcome when administered early after acute myocardial infarction. However, whether &bgr;-blockers actually reduce the myocardial infarction size is still in dispute. Cardiac magnetic resonance imaging can accurately depict the left ventricular (LV) ischemic myocardium at risk (T2-weighted hyperintense region) early after myocardial infarction, as well as the extent of necrosis (delayed gadolinium enhancement). The aim of this study was to determine whether early administration of metoprolol could increase myocardial salvage, measured as the difference between the extent of myocardium at risk and myocardial necrosis. Methods and Results— Twelve Yorkshire pigs underwent a 90-minute left anterior descending coronary occlusion, followed by reperfusion. They were randomized to metoprolol (7.5 mg during myocardial infarction) or placebo. Global and regional LV function, extent of myocardium at risk, and myocardial necrosis were quantified by cardiac magnetic resonance imaging studies performed 4 and 22 days after reperfusion in 10 survivors. Despite similar extent of myocardium at risk in metoprolol- and placebo-treated pigs (30.9% of LV versus 30.6%; P=NS), metoprolol resulted in 5-fold-larger salvaged myocardium (32.4% versus 6.2% of myocardium at risk; P=0.015). The LV ejection fraction significantly improved in metoprolol-treated pigs between days 4 and 22 (37.2% versus 43.0%; P=0.037), whereas it remained unchanged in pigs treated with placebo (35.1% versus 35.0%; P=NS). The extent of myocardial salvage was related directly to LV ejection fraction improvement (P=0.031) and regional LV wall motion recovery (P=0.039) at day 22. Conclusions— Early metoprolol administration during acute coronary occlusion increases myocardial salvage. The extent of myocardial salvage, measured as the difference between myocardium at risk and myocardial necrosis, was associated with regional and global LV motion improvement.

[1]  M. Bristow.  beta-adrenergic receptor blockade in chronic heart failure. , 2000, Circulation.

[2]  R. F. Hoyt,et al.  Cardiac magnetic resonance imaging , 2004, Postgraduate Medical Journal.

[3]  E. Ellerbeck,et al.  Impact of organizational infrastructure on beta-blocker and aspirin therapy for acute myocardial infarction. , 2006, American Heart Journal.

[4]  T. Peter,et al.  Failure of High Doses of Propranolol to Reduce Experimental Myocardial Ischemic Damage , 1978, Circulation.

[5]  V. Fuster,et al.  The utility of magnetic resonance imaging in cardiac tissue regeneration trials , 2006, Nature Clinical Practice Cardiovascular Medicine.

[6]  A. Yıldırır,et al.  Effects of metoprolol therapy on cardiac troponin-I levels after elective percutaneous coronary interventions. , 2006, European heart journal.

[7]  R. Kim,et al.  Transmural Extent of Acute Myocardial Infarction Predicts Long-Term Improvement in Contractile Function , 2001, Circulation.

[8]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.

[9]  R. Kloner,et al.  Infarct Size Reduction by Propranolol before and after Coronary Ligation in Dogs , 1977, Circulation.

[10]  J. Lowe,et al.  The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.

[11]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[12]  J. Willerson,et al.  Propranolol in acute myocardial infarction: the MILIS experience. , 1986, The American journal of cardiology.

[13]  M. Fishbein,et al.  Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. , 1981, American heart journal.

[14]  R. Kim,et al.  Early Assessment of Myocardial Salvage by Contrast-Enhanced Magnetic Resonance Imaging , 2000, Circulation.

[15]  S. Kernis,et al.  Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? , 2004, Journal of the American College of Cardiology.

[16]  M. Domanski,et al.  Treatment of sudden cardiac death. Current understandings from randomized trials and future research directions. , 1997, Circulation.

[17]  F. Van de Werf,et al.  Reduction in infarct size and enhanced recovery of systolic function after coronary thrombolysis with tissue-type plasminogen activator combined with beta-adrenergic blockade with metoprolol. , 1987, Circulation.

[18]  Gervasio A. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[19]  Johan Herlitz,et al.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. , 1985, European heart journal.

[20]  Katherine C. Wu,et al.  Accuracy of Contrast-Enhanced Magnetic Resonance Imaging in Predicting Improvement of Regional Myocardial Function in Patients After Acute Myocardial Infarction , 2002, Circulation.

[21]  R. Califf,et al.  International variation in the use of evidence-based medicines for acute coronary syndromes. , 2003, European heart journal.

[22]  T. Yue,et al.  Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[23]  F. Van de Werf,et al.  Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. , 1993, Journal of the American College of Cardiology.

[24]  Å. Hjalmarson,et al.  Myocardial infarction. Effects of beta-blockade. , 1991, Circulation.

[25]  A. Kini,et al.  Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. , 2000, Circulation.

[26]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .

[27]  K. Scheel,et al.  Functional anatomical site of intramural collaterals in dogs. , 1990, The American journal of physiology.

[28]  Oliver Turschner,et al.  The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. , 2004, European heart journal.

[29]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[30]  K. Swedberg,et al.  Early treatment with thrombolysis and beta-blockade in suspected acute myocardial infarction: results from the TEAHAT Study. , 1991, Journal of internal medicine. Supplement.

[31]  R. Peto,et al.  Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. , 1983, Circulation.

[32]  E. Braunwald,et al.  Enhancement of salvage of reperfused myocardium by early beta-adrenergic blockade (timolol). , 1984, Journal of the American College of Cardiology.

[33]  R. Lyons.  Reduction of infarct size with the early use of timolol in acute myocardial infarction. , 1984, The New England journal of medicine.

[34]  Deepak L. Bhatt,et al.  Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.

[35]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[36]  M. Nieminen,et al.  Failure of pindolol and metoprolol to reduce the size of non-reperfused infarcts in dogs using area at risk techniques. , 1984, Cardiovascular research.

[37]  J. J. Griffin,et al.  Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[38]  J. Schulz-Menger,et al.  Delayed Enhancement and T2-Weighted Cardiovascular Magnetic Resonance Imaging Differentiate Acute From Chronic Myocardial Infarction , 2004, Circulation.

[39]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[40]  G. Ewy,et al.  Failure of intravenous metoprolol to limit acute myocardial infarct size in a nonreperfused porcine model. , 1995, American heart journal.

[41]  Olga Bondarenko,et al.  Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. , 2003, Journal of the American College of Cardiology.

[42]  T J Brady,et al.  Effect of hyperosmotic mannitol on magnetic resonance relaxation parameters in reperfused canine myocardial infarction. , 1989, Magnetic resonance imaging.

[43]  R. Kloner,et al.  Cardiac protection during acute myocardial infarction: where do we stand in 2004? , 2004, Journal of the American College of Cardiology.

[44]  J. Gili,et al.  Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. , 1993, Cardiovascular research.

[45]  B. Uretsky,et al.  Distal Myocardial Protection During Percutaneous Coronary Intervention With an Intracoronary &bgr;‐Blocker , 2003, Circulation.

[46]  R. Jennings,et al.  The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[47]  L. Tavazzi,et al.  The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. , 2006, European heart journal.

[48]  R. Kim,et al.  Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. , 2000, Journal of the American College of Cardiology.

[49]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[50]  Richard D. White,et al.  Tracking and Analysis of Cine-Delayed Enhancement MR , 2005, MICCAI.

[51]  A. Jaffe,et al.  Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. , 1984, The New England journal of medicine.